Trial NCT03860207

View at ClinicalTrials.gov 
Org. Study IDs: 18-034

Last trial update was posted on 2023-09-13

MeSH Interventions

Antibodies Antibodies, Bispecific Immunoglobulins

MeSH Conditions

Neuroblastoma Osteosarcoma

Other Conditions

Other Solid Tumor Cancers

Stopping Reasons

study terminated due to business priorities

Limitations And Caveats

The study was terminated after 11 subjects due to a business strategy decision. At this point the maximum tolerated dose was not established.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID